These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15073697)

  • 1. Heparin resistance and antithrombin: should it still be called heparin resistance?
    Levy JH
    J Cardiothorac Vasc Anesth; 2004 Apr; 18(2):129-30. PubMed ID: 15073697
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass.
    Linden MD; Schneider M; Baker S; Erber WN
    J Cardiothorac Vasc Anesth; 2004 Apr; 18(2):131-5. PubMed ID: 15073698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass.
    Finley A; Greenberg C
    Anesth Analg; 2013 Jun; 116(6):1210-22. PubMed ID: 23408671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating heparin resistance with antithrombin or fresh frozen plasma.
    Spiess BD
    Ann Thorac Surg; 2008 Jun; 85(6):2153-60. PubMed ID: 18498854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members.
    Sniecinski RM; Bennett-Guerrero E; Shore-Lesserson L
    Anesth Analg; 2019 Aug; 129(2):e41-e44. PubMed ID: 30540616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin?
    Tanaka KA; Sniecinski R
    Anesthesiology; 2006 Aug; 105(2):428; author reply 428-9. PubMed ID: 16871082
    [No Abstract]   [Full Text] [Related]  

  • 8. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
    Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
    Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
    [No Abstract]   [Full Text] [Related]  

  • 9. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin resistance, antithrombin III treatment, and activated clotting time values.
    Kanbak M
    Anesth Analg; 1998 Nov; 87(5):1215. PubMed ID: 9806721
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the activated clotting time dangerous?
    Metz S
    Anesthesiology; 2005 Oct; 103(4):903-4; author reply 904. PubMed ID: 16192793
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass.
    Nicholson SC; Keeling DM; Sinclair ME; Evans RD
    Br J Anaesth; 2001 Dec; 87(6):844-7. PubMed ID: 11878684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excessive requirement for heparin during cardiac surgery.
    Chung F; David TE; Watt J
    Can Anaesth Soc J; 1981 May; 28(3):280-2. PubMed ID: 7237224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heparin resistance during cardiopulmonary bypass].
    Maeda R; Fukuda H; Nakaigawa Y; Hiruta M; Hirabayashi Y; Seo N
    Masui; 2003 Sep; 52(9):1003-5. PubMed ID: 14531265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
    Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 18. Heparin Resistance - Clinical Perspectives and Management Strategies.
    Levy JH; Connors JM
    N Engl J Med; 2021 Aug; 385(9):826-832. PubMed ID: 34437785
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of real-world heparin resistance and anticoagulation management prior to cardiopulmonary bypass: report from a nationwide survey by the Japanese Association for Thoracic Surgery heparin resistance working group.
    Ito K; Sasaki K; Ono M; Suzuki T; Sakamoto K; Okamoto H; Katori N; Momose N; Araki Y; Tojo K; Ieko M; Komiyama Y; Saiki Y
    Gen Thorac Cardiovasc Surg; 2024 Jan; 72(1):8-14. PubMed ID: 37195584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance during cardiopulmonary bypass-assisted cardiac surgery.
    McNair E; Marcoux JA; Bally C; Gamble J; Thomson D
    Perfusion; 2016 Apr; 31(3):189-99. PubMed ID: 25934498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.